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Abstract: The development of new strategies for enhancing drug delivery to the brain represents
a major challenge in treating cerebral diseases. In this paper, we report on the synthesis and
structural characterization of a biocompatible nanoparticle (NP) made up of poly(lactic-co-glycolic
acid) (PLGA)-polyethylene glycol (PEG) co-polymer (namely PELGA) functionalized with the
membranotropic peptide gH625 (gH) and the iron-mimicking peptide CRTIGPSVC (CRT) for
transport across the blood-brain barrier (BBB). gH possesses a high translocation potency of the
cell membrane. Conversely, CRT selectively recognizes the brain endothelium, which interacts
with transferrin (Tf) and its receptor (TfR) through a non-canonical ligand-directed mechanism.
We hypothesize that the delivery across the BBB of PELGA NPs should be efficiently enhanced by
the NP functionalization with both gH and CRT. Synthesis of peptides and their conjugation to
the PLGA as well as NP physical-chemical characterization are performed. Moreover, NP uptake,
co-localization, adhesion under dynamic conditions, and permeation across in vitro BBB model are
evaluated as a function of gH/CRT functionalization ratio. Results establish that the cooperative
effect of CRT and gH may change the intra-cellular distribution of NPs and strengthen NP delivery
across the BBB at the functionalization ratio 33% gH–66% CRT.
Keywords: nanoparticles; peptides; blood-brain barrier; drug delivery; transport
1. Introduction
The treatment of cerebral diseases such as brain tumors, HIV encephalopathy, epilepsy,
cerebrovascular diseases, and neurodegenerative disorders is severely hindered due to the presence of
the blood-brain barrier (BBB). The role of this barrier is to preserve brain homeostasis and to prevent
toxic substances and invading organisms from reaching the brain. Therefore, an important feature
of this barrier is the low and selective permeability to molecules, which excludes therapeutics from
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entering the brain parenchyma [1]. To date, the most common strategies to overcome this problem
include drug administration directly into the CNS such as the temporary and local breakage of the
endothelium, intracerebral injections, or the introduction of a slow-release implant into the brain [2].
Nanomedicine applied to the treatment of the CNS diseases provides a promising alternative strategy
to conventional invasive and low effective brain treatments. In particular, the targeted-delivery of
drugs to their action site by using nanocarriers such as NPs, dendrimers, nanogels, and nanoemulsions
is able to combine the advantages of tissue targeting, drug loading, passing of BBB, and the reduction
of side effects [3]. Usually, NPs enter the cell by using the endocytic pathway [4]. After endocytosis,
the endosomes fuse with lysosomes where the acidification (pH < 5.5) allows either the degradation of
the endosomes content or the delivery of endosomes cargo across the BBB [5]. In order to escape the
endo-lysosomal pathway and to deliver the cargo across the BBB, the physical-chemical modulation of
the NP surface plays a major role in mediating their interactions with the cell membrane including their
intracellular fate. A key mechanism to improve the transport of NPs is by adding bioactive peptides
such as the cell penetrating peptides (CPPs) to their surface. CPPs are short peptides of 5–40 amino
acids provided with a net positive charge, helical moment, and amphipathic nature. These peptides
enter the cells presumably by recognizing their cationic groups by negatively charged residues exposed
on the cell membrane. Alternatively, membranotropic CPPs can efficiently cross the biological
membranes by promoting the reorganization of plasma membrane lipid domains, which causes
a temporary increase of membrane permeability [6–8]. Membranotropic CPPs take advantage of
non-toxic components of neurotoxins to overcome the BBB reaching the CNS, which circumvents
endosomal entrapment [9]. Among these, the gH peptide, which is derived from the glycoprotein
of the Herpes simplex virus type 1, merges with model membranes and is able to traverse the
membrane bilayer and to transport a cargo by escaping the degradation pathway of lysosomes [6,10,11].
In particular, in previous works, we demonstrated that the gH membranotropic peptide facilitates the
delivery of polystyrene NPs across the murine BBB endothelium, which leads to a significantly higher
cellular uptake by crossing through a non-conventional path [11] both in static [12] and dynamic [13]
conditions. Moreover, in the case of metallic platinum ultrasmall NPs, gH partially increases their
cytosolic delivery and anti-oxidant properties in Hela cells [14]. Furthermore, we showed that the
peculiar mechanism of the entrance of NPs into the cells can easily be translated to soft matter
nano-carriers such as oil/water nano-emulsions to enhance the cytosolic delivery of curcumin [15].
In this work, in order to translate the gH-based delivery platform to biodegradable systems made
up of FDA-approved materials, we synthesized PELGA-NPs functionalized with gH, which has never
been reported before in a BBB in vitro analysis. Due to their non-specific affinity to different cells,
gH-mediated brain delivery systems could show a non-specific distribution in the human body after
systemic administration. To overcome this drawback, the synthesis of nanocarriers functionalized
with specific receptor-mediated transcytosis (RMT) ligands offers the possibility to target the cerebral
endothelium by recognizing specific receptors overexpressed on the cells. The exploitation of RMT
ligands such as Tf, insulin, and low density lipoprotein (LDL) has already been proposed for the
transport of biologics into the brain, which allows NP delivery to the CNS [16–19]. The dual
functionalization of PELGA NPs has been previously investigated [20–22]. Usually, specific ligands
have high affinity for selective receptors, which promotes high cellular uptake of NPs through
endocytosis mechanisms. However, often they are inefficient for enhancing transcytosis of NPs likely
because of their endo-lysosomal compartmentalization. In fact, the main limitation of RMT is associated
with low efficiency of BBB crossing and achievement into the CNS [23]. To date, only a few studies have
clearly demonstrated the therapeutic effect of targeted nanocarriers in treating cerebral diseases [24,25].
Researchers have focused substantial efforts on identifying new BBB RMT targets. The most common
method to identify them is through the screening of combinatorial peptide libraries. Staquicini et al.
identified a new sequence, CRT (CRTIGPSVC), which is able to selectively target the brain endothelium
and enhance brain crossing of viral particles [26]. CRT is a cyclic iron-mimicking peptide used as
RMT-targeting ligand. CRT binds to apo-Tf causing it to adopt its iron-bound holo-Tf conformation,
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which recognizes TfR and gains access to the brain. TfR is highly expressed on immature erythroid
cells, placental tissue, and rapidly dividing cells, which are both normal and malignant. Furthermore,
it is expressed on hepatocytes and endothelial cells of the BBB [27,28]. Kang et al. demonstrated
that the surface functionalization with the CRT peptide is able to specifically transport PELGA NPs
across the BBB in vitro and in vivo [29]. Zhang et al. demonstrated that the conjugation of CRT on the
surface of PLA-PEG NPs promotes cellular uptake and in vivo brain accumulation [30]. In this work,
in order to avoid nanoparticle accumulation inside lysosomal compartments and overcome the gH
lack of targeting specificity, the nanoparticles were functionalized with both gH and CRT peptides.
Utilized NPs were prepared by mixing two polymeric species, i.e., the PELGA (Scheme 1A) and the
functionalized PLGA-x where x is gH, CRT, rhodamine, or ethylenediamine (respectively E, D, C, B
Scheme 1). We prepared and tested dual-functionalized NPs contained on the PLGA fraction including
both the gH and CRT peptide tails. Three different gH/CRT ratios were synthesized: (i) 50%–50%
(ii) 33%–66% (iii) 66%–33%. The hydrodynamic diameter and Z-potential, as well as the composition
and functionalization of all the NPs prepared and tested are reported in Tables 1 and 2, respectively.
The effects of the functionalization on the targeting under dynamic conditions and the penetration
of PELGA NPs through an in vitro BBB model based on the mouse brain endothelial bEnd.3 cells
were evaluated.
Scheme 1. PLGA co-polymers and conjugates: (A) PLGA-PEG (PELGA) co-polymer, (B) PLGA-amine,
(C) PLGA-rhodamine, (D) PLGA-CRT, and (E) PLGA-gH.
Table 1. Hydrodynamic diameter (HD) and Z-potential values of the different NP formulations.
Data are reported as the mean of three different measurements ± standard deviation (SD).
NP HD (nm)± SD PDI
Z-Potential (mV)
± SD
Blank 88.24 ± 1.62 0.15 −27.40 ± 0.66
CRT 92.06 ± 1.53 0.15 −26.10 ± 1.17
gH 84.53 ± 0.60 0.14 −13.83 ± 0.11
gH/CRT_66/33 80 ± 1 0.16 −22.4 ± 0.5
gH/CRT_50/50 78 ± 2 0.14 −23.8 ± 0.9
gH/CRT_33/66 76 ± 1 0.13 −20.0 ± 0.5
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Table 2. Amount of co-polymers used for the different NP formulations.
NP PELGA(mg)
PLGA-Rho
(mg)
PLGA-gH
(mg)
PLGA-CRT
(mg)
PLGA
(mg) mg tot
Blank 1 0.4 - - 0.8 2.2
gH 1 0.4 0.4 - 0.4 2.2
CRT 1 0.4 - 0.4 0.4 2.2
gH/CRT_66/33 1 0.4 0.4 0.2 0.2 2.2
gH/CRT_50/50 1 0.4 0.4 0.4 - 2.2
gH/CRT_33/66 1 0.4 0.2 0.4 0.2 2.2
2. Results
2.1. NP Building Blocks and NMR Analysis
Pure PLGA co-polymers and conjugates (Scheme 1) were synthesized and obtained in sufficient
yield (from 80% to 85%). NP precursors were prepared through ester or amide linkage to the
carboxylic group of PLGA, which optimized a previously reported synthesis [31,32]. In particular,
Oxima Pure® was used as an additive instead of 1-hydroxybenzotriazole (HOBt) both in peptide
synthesis and in conjugation coupling reaction. It showed clear superiority to HOBt (which have
been reported to exhibit explosive properties) [33] in terms of suppression of racemization, coupling
efficiency, and safety [34]. With regard to PLGA-rhodamine (Scheme 1C) and PLGA-gH (Scheme 1E),
an ethylenediamine linker between the two carboxylic groups of conjugates was previously added
(PLGA-amine–Scheme 1B).
The chemical characterization of synthesized NP precursors was carried out using two techniques.
First, the peptide synthesis step and the CRT cyclization reaction were followed by LC-MS in order to
confirm peptide sequences and disulfide bond formation (Figure S1). Then 1H-NMR spectroscopy was
used after dialysis purification of the co-polymers in order to assess the products purity. The presence
of proton signals belonging to the CRT and gH peptides (see the NH amide protons in the orange and
blue squared insets, respectively, in Figure 1) or to the aromatic protons of rhodamine (purple and red
squared inset in Figure 1) confirmed the success of the coupling step for all the PLGA conjugates.
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Figure 1. 1H-NMR spectra of synthesized PLGA conjugates showed in Scheme 1. In every spectrum,
peaks related to PLGA were marked with black triangles (N). (I) PELGA co-polymer with PEG signal
3.64 ppm (N), (II) PLGA-rhodamine with rhodamine aromatic signals highlighted in magenta expansion
square, (III) PLGA-CRT and (IV) PLGA-gH with peptide amide backbone signals highlighted in orange
and blue expansion squares, respectively.
2.2. NP Characterization
The prepared NPs were characterized in size and surface charge by DLS and Z-potential
measurements in aqueous medium. The hydrodynamic diameter (HD) of NPs after filtration was
found to be below 100 nm and ranged from 70 nm and 95 nm for all the particle formulations. Table 1
reports the HD values of the different NPs. Moreover, all the suspensions showed polydispersity
values of ca. 0.15, which indicates a narrow distribution of the particle size. Z-potential measurements
indicated a negative surface charge around −20 mV for all NP types with slight differences among the
formulations due to the presence of the peptides. A more positive charge was shown for gH NPs and
this is probably due to the positive charge of the amino-acid chain. The stability of NP suspensions
was monitored over time.
2.3. NP Intracellular Distribution
Indirect immunofluorescence against endocytic markers may give information about the endocytic
mechanisms underlying nanoparticle cellular uptake. In order to investigate the intracellular
distribution and fate of NPs, co-localization experiments with lysosomes were performed. After
24 hours of incubation, which is shown in Figure 2, blank, CRT, gH, gH/CRT_66/33, gH/CRT_50/50,
and gH/CRT_33/66 NPs were internalized by the cells.
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Figure 2. Co-localization of blank NPs (a,d), CRT NPs (b,e), gH NPs (c,f), gH/CRT_33/66 NPs (g,j),
gH/CRT_50/50 NPs (h,k), gH/CRT_66/33 NPs (i,l) with lysosomes after 24 h of incubation in bEnd.3
cells. Red: NPs, green: LAMP-2, blue: nuclei. Bar 50 µm.
NPs showed different intracellular localization. Both blank and CRT NPs enter bEnd.3 cells
and partially co-localize with LAMP-2 glycoprotein, which is a marker of lysosomal compartments.
Conversely, gH NPs showed a main cytoplasmic distribution and no significant co-localization with
lysosomes was noticed, according to previous studies [11,12]. Localization of dual-functionalized NPs
Molecules 2018, 23, 1655 7 of 17
changed as a function of the formulation. More precisely, lysosomal distribution increased with the
amount of CRT in the formulation. Likewise, cytoplasmic distribution increased by increasing the gH
amount. In this way, it became more similar to the mono-functionalized NPs.
2.4. NP Transport across the BBB Endothelium
bEnd.3 cells formed a confluent monolayer that was able to mimic the properties of the BBB
endothelium when cultured on porous inserts [35,36]. The development of tight junctions was followed
by using TEER measurements. After 7 days of cell seeding, TEER was found to be 21.67 ± 4.94 Ω cm2
(n = 6), which reached a value comparable to reported studies [37]. Therefore, in order to study if the
functionalization could affect the ability to cross the in vitro BBB, transport experiments through the
bEnd.3 confluent monolayer were performed. Data reported in Figure 3 demonstrated that CRT NPs
and gH/CRT_33/66 NPs crossed the endothelial layer more efficiently when compared to blank NPs.
Figure 3. Permeability of bEnd.3 cell monolayer to blank, CRT, gH, gH/CRT_33/66, gH/CRT_50/50,
and gH/CRT_66/33 functionalized NPs. * p = < 0.05, ** p = < 0.0005.
In particular, among mono-functionalized NPs, CRT NPs showed the highest ability in NP
transport across the in vitro BBB endothelium with a permeability of 4.64 × 10−6 cm/s. No significant
increase in permeability of the barrier was found for gH functionalization (4.40× 10−6 cm/s) compared
to the blank NPs (3.17 × 10−6 cm/s). On the other hand, for the dual-functionalized NPs, the
permeability increment grew by decreasing the CRT amount in the gH/CRT ratio. More precisely,
permeability of the BBB endothelium was 7.48 × 10−6 cm/s for gH/CRT_33/66, 4.57 × 10−6 cm/s
for gH/CRT_50/50 NPs, and 3.50 × 10−6 cm/s for gH/CRT_66/33. Therefore, gH/CRT_33/66 NPs
showed the highest of trans-endothelial crossing ability. Permeability results suggested a cooperative
effect on BBB crossing of gH and CRT peptides when exposed on NPs in percentages of 33% to
66%, respectively.
2.5. NP Adhesion to the BBB Endothelium in Flow Conditions
In vivo, the brain endothelium is exposed to the bloodstream. Therefore, in physiological
conditions, NPs should recognize and bind the endothelial wall under dynamic forces before crossing
the BBB. To address this issue, we investigated how the surface functionalization could affect the
targeting ability of NPs to the cerebral endothelium by using a parallel plate flow chamber Glycotech
system, which is a commercial device mimicking hydrodynamic conditions in the microcirculation.
Among dual-functionalized NPs, gH/CRT_33/66 formulation was chosen for the dynamic adhesion
assay due to the highest ability to transport the NPs across the in vitro BBB. The volumetric flow rate
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Q (10 µL/min) was fixed to be equal for all the experiments. Based on these data, the mean velocity is
shown below.
U =
Q
wh
, (1)
within the chamber, it was ∼=0.066 mm/s. The shear rate is shown below.
S =
6Q
h2w
, (2)
this was 1.55 s−1 and the shear stress at the wall is shown below.
τw = u S, (3)
this was 1.86 × 10−3 Pa.
The mean velocity used for the experiments was comparable with the blood velocity in the human
capillary vessels that is calculated between 0.01 mm/s and 0.1 mm/s [38]. The shear rate and the shear
stress at the wall were sufficiently small to allow adhesion of nanoparticles to endothelial cells [39].
The Reynolds number is clearly associated with a laminar flow and was 0.035. In Figure 4a–h, some
representative confocal images of BBB endothelia after 1 hour of treatment with blank (Figure 4a,e),
gH (Figure 4b,f), CRT (Figure 4c,g), and gH/CRT_33/66 (Figure 4d,h) NPs were reported. The images
showed a higher red fluorescence related to NPs for cells treated with CRT and gH/CRT NPs than blank
and gH NPs. To quantify NP adhesion, 10 confocal images of different areas of the endothelial layers
treated with each NP type were acquired and analyzed by ImageJ software. Results of fluorescence
image analysis demonstrated that, among mono-functionalized NPs, CRT NPs possessed the higher
adhesion ability to the bEnd.3 monolayer compared to blank NPs. As shown in Figure 4i, the calculated
fluorescence percentage of CRT NPs was 0.79% against 0.44% of blank NPs. Conversely, no significant
increase in adhesion for gH NPs with a fluorescence percentage of 0.60% was found in comparison
with blank NPs. For dual-functionalized gH/CRT_33/66 NPs, the percentage of adhesion was 0.97%.
Therefore, adhesion assay results indicated that the presence of the gH peptide did not enhance
significantly the targeting of the cerebral endothelium under dynamic conditions.
Figure 4. Cont.
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Figure 4. (a–h) Confocal images of NPs in bEnd.3 after a 1-hour experiment in flow conditions.
(a,e) blank NPs, (b,f) gH NPs, (c,g) CRT NPs, (d,h) gH/CRT_33/66. Red: NPs, blue: nuclei. Bar 50 µm.
(i) Percentage of fluorescence intensity of NPs adherent to bEnd.3 layer after 1 h under flow condition
(flow rate 10 µL/min). * p < 0.05, ** p < 0.0005; ns = not significant.
3. Discussion
The nanoparticle ability to recognize and cross the brain endothelium is an important requirement
for successful brain therapies. The design of targeted-delivery carriers has garnered significant
attention in recent years because of the potential to achieve highly localized delivery to brain
endothelium [17,23]. The physical-chemical modulation of the surface of nanocarriers offers the
possibility to restrict the biological effect of the therapy to a specific type of cells by avoiding
the potentially toxic contact with cells not of interest. The challenge to win is the achievement
of CNS, which reaches the threshold of a sufficient drug concentration in order for it to be effective,
which avoids side effects to healthy tissues. To overcome these limitations, biodegradable PELGA
nanoparticles, which provide good biocompatibility, high reproducibility, great pay-load properties,
and easiness in functionalization were used as nanocarriers. In particular, we recently reported
on the versatility of PELGA nanoparticles as efficient drug delivery systems [32–39]. In this work,
PELGA NPs were synthetized by using the nanoprecipitation method and combining co-polymers
and peptide-functionalized polymers as building blocks. This method allowed us to bypass the
functionalization step, which reduces the time required for NP production. The data presented
in this paper characterized a new delivery platform to promote brain penetration. Recent studies
based on this perspective focused increasing attention on developing several strategies in order to
deliver drugs across the BBB by combining targeting and crossing strategies. Zheng et al. designed
double functionalized liposomes with Transferrin (Tf) and the CPP TAT to promote their translocation
across the BBB [40,41]. Data of liposome biodistribution ex vivo showed that Tf/TAT liposomes
accumulated the most in the brain when compared to controls. However, a non-specific accumulation
in other organs such as lung and liver after 12 hours was also detected. Despite several studies
proving the effectiveness of CPPs such as TAT in promoting the NP transport across the BBB [42],
the TAT peptide demonstrated the involvement of the endocytosis pathway in the internalization
mechanism [43–45], which allowed for the storage of the cargo inside endosomes and lysosomes.
Therefore, only a small quantity of drugs are able to cross the cell and reach the brain. In this context,
in order to overcome the limitation of TAT in the involvement of the endocytic pathway, we chose gH
as CPP, which was widely characterized in previous works [11–15]. gH facilitates NP delivering across
the BBB, which leads to a significant higher cellular uptake and crossing. It escapes the endo-lysosomal
entrapment. Therefore, gH is able to overcome the limitations of TAT on the endocytic mechanism of
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internalization. As described above, in our previous validation studies, we showed that gH enters cells
and is able to transport cargo across cells. For a targeted NP delivery, among the various methods used
by researchers to recognize the cerebral endothelium, Tf/TfR is one of the most common strategies
for active transport [46–48]. In order to target the cerebral endothelium, we chose the iron-mimicking
peptide CRT, which is able to target the Tf/TfR complex. The contribution of both gH and CRT peptides
in the trans-endothelial ability to cross the in vitro BBB in dual-functionalized NP formulations was
tested and compared to blank and mono-functionalized nanoparticles. To this aim, we first performed
cellular uptake and lysosomal co-localization experiments of gH/CRT co-modified NPs in three
different ratios, which are 50/50, 33/66, and 66/33. These formulations were compared with CRT
or gH mono-functionalized NPs and non-functionalized blank NPs. Confocal images showed that
functionalized-NPs had different intra-cellular distributions. In particular, the presence of the gH
peptide played a key role in controlling the NP intracellular fate. In fact, it reduced the lysosomal
storage of NPs. The specific action of the gH peptide in decreasing NP accumulation in lysosomes
was also confirmed by transport experiments across the in vitro BBB. Moreover, the presence of CRT
promoted NP transport across the BBB, but the co-presence of gH was able to further enhance the
crossing. This effect was shown when gH/CRT peptides were exposed in percentages of 33% or 66%
on the NPs. Therefore, the NP transport results confirmed our initial hypothesis. The cooperative
effect was not evident in the case of 50%/50% and 66%/33% NP formulations. Further investigations
such as the analysis of conformation and exposure of peptides on NP surface are needed to elucidate
the higher performance of the gH/CRT_33/66 NP formulation compared to others. gH is a 19 residues
peptide with helical moment while CRT is a cyclic peptide of nine amino-acids. Likely, the lower
concentration of gH in gH/CRT_33/66 NP formulation than gH/CRT_50/50 and gH/CRT_66/33 NPs
allows for the reduction of the steric hindrance, which promotes the correct exposure of both peptides
on the NP surface during the preparation. Therefore, the peptides had more conformational freedom
and a higher ability to perform their proper function. We also investigated if the contribution of gH
in increasing NP transport was due to an enhancement in the NP association to the endothelial cell
layer by using an NP adhesion assay under dynamic conditions. Data from these assays indicated
that the percentage of gH NPs was quite similar to blank NPs and the percentage of gH/CRT_33/66
was similar to CRT NPs. These findings clearly indicated that the presence of gH on the PELGA NP
surface did not enhance the recognition of the endothelial cells. Therefore, it may be hypothesized that
the enhancement in NP crossing cannot be ascribed to the targeting enhancement, but can be ascribed
to the mechanism of the gH peptide which reduced lysosomal escaping and promoted NP transport
across the in vitro BBB. However, in a prior study, we demonstrated that the decoration of polystyrene
NPs with the gH625 peptide enhanced the adhesion of those particles to the endothelial layer and the
BBB crossing in flow conditions [13]. This suggests an effect on the nature of the particle in affecting
the functionality of cell-penetrating peptides. Taken altogether, our results demonstrated that the dual
functionalization strategy based on the use of a cell membrane penetrating and a targeting peptide,
which are known as gH and CRT, enhanced the recognition under static and dynamic conditions and
the transport across the BBB endothelium of PELGA NPs.
4. Materials and Methods
4.1. Reagents and Materials
Equimolar uncapped poly(D,L-lactide-co-glycolide) (PLGA) (Resomer RG502H, average Mw
12 kDa) was purchased from Boehringer Ingelheim (Ingelheim, Germany). Polyethylene
glycol (PEG, Mw 1500 Da), Ethylenediamine (en), N,N-diisopropylethylamine (DIPEA),
O-benzotriazole-N,N,N′,N′-tetramethyluronium-hexafluoro-phosphate (HBTU), Ethyl 2-cyano-2-
(hydroxyimino) acetate (Oxyma Pure Novabiochem®), anhydrous N,N-dimethyl-formamide (DMF),
Acetonitrile (ACN), N,N′-Diisopropylcarbodiimide (DIC), N,N′-Dicycloexylcarbodiimide (DCC),
Rhodamine B, 4-(dimethylamino) pyridine (DMAP), Dichloromethane (DCM), Dimethylsulfoxide
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(DMSO), Sodium carbonate (Na2CO3), Piperidine, Trifluoroacetic acid (TFA), Formic acid, HPLC-grade
water, and all buffer solutions were purchased from Sigma-Aldrich S.r.l.(Milan, Italy). All Fmoc-
aminoacids were purchased from IRIS Biotech GmbH (Marktredwitz, Germany). Dialysis bag MWCO
6000–8000 Da were purchased from Spectrum Europe B.V. (Breda, The Netherlands). Distilled and
deionized water used Millipore Milli-RO 10 Plus from Merck S.p.a. (Milan, Italy) at 18 MΩ resistance.
Amicon® Ultra-4 centrifugal filters were purchased from Merck S.p.a. (Milan, Italy).
4.2. Peptide Synthesis and Characterization
CRT (Ac-CRTIGPSVC-βAK-CONH2) and gH (Ac-HGLASTLTRWAHYNALIRAFGGG-COOH)
peptides were synthesized using the standard solid-phase-9-fluorenyl methoxy carbonyl (Fmoc)
procedure and were obtained with good overall yields (35%–40%). The β-Alanine-Lys (as regards
CRT peptide) and the Gly3 (for gH625 peptide) residues acted as spacer units between polymer and
peptide active sequences in order to retain the native peptide conformation when conjugated to the
particle surface.
The syntheses were performed by using the Biotage®Syro Wave™ peptide synthesizer (Biotage,
Uppsala, The Netherlands). Rink Amide and Wang resin was used as a solid-phase support for CRT
and gH peptide, respectively. Previously, the C-terminal glycine residue (10 eq) of the gH peptide was
manually attached to an equivalent amount of Wang resin using Oxima Pure® (10 eq), DIC (10 eq),
and DMAP (0.4 eq). The Fmoc protecting group was removed using piperidine 40% (v/v) solution in
DMF. Peptides were cleaved from resin using the TFA/TIS/H2O (95/2.5/2.5) solution and precipitated
in ice-cold diethyl ether. Purified CRT peptide was obtained by using RP-HPLC starting from 5/95
(v/v) acetonitrile (ACN)/water solution containing 0.1% v/v TFA. For the purification of the gH
peptide, a 20/80 ACN/water solution with 0.1% v/v TFA was used. Peptides were lyophilized and
then characterized using ESI-LC-MS. These analyses were carried out by injecting aqueous solutions
of peptides into Agilent ZORBAX EclipsePlus C18 RRHD (1.8 µm, 2.1 × 50 mm) (Agilent, Santa Clara,
CA, USA) eluted with solvent solution of H2O and ACN containing 0.1% v/v of formic acid. A linear
gradient of 20%–80% of ACN over 8 min at a flow of 150 µL/min was used.
MS for the CRT peptide was calculated for [M + H]+ = 1176.43 m/z; found (ESI) [M + H]+ =
1175.78 m/z, [M + 2H]2+ = 588.43 m/z, [M + 3H]3+ = 392.64 m/z. MS for the gH peptide was calculated
for [M + H]+ = 2512.79 m/z; found (ESI) [M + 2H]2+ = 1256.68 m/z, [M + 3H]3+ = 838.12 m/z, [M + 4H]4+
= 628.84 m/z (Supplementary Materials S1).
4.3. Peptide Cyclization
The purified CRT peptide was cyclized by the air-oxidation method to allow the formation
of the intra-chain disulfide bond between the two cysteine residues. Briefly, the cysteinyl peptide
(0.1 mg/mL) was dissolved in 0.1 M sodium carbonate (pH 8) and left to stand open to the atmosphere
under vigorous magnetic stirring until the reaction was complete (48 h). The reaction progress was
monitored by the LC-MS analysis. MS for CRT-cyclized peptide was calculated for [M + H]+ =
1174.43 m/z. It was found that (ESI) [M + H]+ = 1173.77 m/z, [M + 2H]2+ = 587.43 m/z, and [M + 3H]3+
= 391.97 m/z. Lastly, the CRT-peptide was purified and lyophilized as described above. The product
was obtained with 86% yield.
4.4. Synthesis of Co-Polymers and Conjugates
4.4.1. PELGA
PLGA-PEG co-polymer (namely PELGA) was synthesized via a coupling reaction between PLGA
and PEG [1]. The carboxyl group of PLGA reacted with the terminal hydroxyl group of PEG. 1 eq of
PLGA, 4 eq of PEG, 0.4 eq DMAP, and 2 eq of DCC were dissolved in 10 mL of anhydrous DCM. After
the reaction (2 days, RT, inert atmosphere), the residual DCC was changed into dicyclohexylcarbodiurea
(DCU) by adding 10 µL of bi-distilled water. Then DCM was evaporated and the mixture was dissolved
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in 10 mL of DMSO and then filtrated and dialyzed (MWCO 6–8 kDa) for 1 day against ACN and
for 2 days against water. The pure product was recovered after lyophilization and its identity was
confirmed by using 1H-NMR spectroscopy (600 MHz, CDCl3): δ ppm 5.30–5.13 (PLGA, CH), 4.92–4.60
(PLGA, CH2), 3.64 (PEG, CH2), 1.59 (PLGA, CH3).
4.4.2. PLGA-Amine
PLGA was functionalized with ethylenediamine (en), which acts as a bridge between PLGA and
rhodamine (or peptide C-terminal) carboxylic groups. In addition, 30 mg of PLGA 502 h, 10.3 mg of
DCC, 8.7 µL of DIPEA, 10.0 µL of ethylenediamine were dissolved in 2.5 mL of anhydrous DCM. After
the reaction (1 day, RT, inert atmosphere), the residual DCC was changed into dicyclohexylcarbodiurea
(DCU) by adding 10 µL of bi-distilled water. The solution was filtered, precipitated dropwise into cold
methanol, centrifuged, and then placed under vacuum overnight. The identity of the pure product was
confirmed by using 1H-NMR spectroscopy (600 MHz, DMSO-d6): δ ppm 8.13 (en, amide), 5.26–5.10
(PLGA, CH), 4.95–4.75 (PLGA, CH2), 3.14 (2 × CH2 overlapped, en), 1.44 (PLGA, CH3).
4.4.3. PLGA-Rhodamine
The PLGA-Rhodamine conjugation was performed by a standard coupling procedure.
PLGA-amine (1 eq), HBTU (5 eq), DIPEA (10 eq), and rhodamine-B (5 eq) reacted in anhydrous
DMSO for 24 h at RT and then purified by dialysis bags (MWCO 6–8 kDa) against water for 3 days.
1H-NMR (600 MHz, CDCl3): δ ppm 8.42, 7.85, 7.05, and 6.92 (rhodamine aromatic proton), 5.30–5.13
(PLGA, CH); 4.92–4.60 (PLGA, CH2), 4.30 (rhodamine CH2), 3.78 (rhodamine CH3), 3.42 (en, CH2),
1.59 (PLGA, CH3).
4.4.4. PLGA-Peptide Conjugates
PLGA-Peptide conjugates were synthesized using a standard HBTU coupling procedure. For the
CRT peptide, PLGA (1 eq), HBTU (5 eq), Oxima Pure® (5 eq), DIPEA (10 eq), and Peptide (1.5 eq)
were dissolved in anhydrous DMSO for 48 h at RT. For the gH peptide, the PLGA-amine 2 eq of
peptide was used. Adducts were purified from unreacted reagents using dialysis bags (MWCO
6–8 kDa) against pure water and lyophilized. The reaction products were confirmed by using 1H-NMR
spectroscopy. PLGA-CRT: 1H-NMR (600 MHz, DMSO-d6): δ ppm 8.50–6.00 (peptide amide backbone),
5.28–5.14 (PLGA, CH), 4.96–4.84 (PLGA, CH2), and 1.47 (PLGA, CH3). PLGA-gH: 1H-NMR (600 MHz,
DMSO-d6): δ ppm 8.50–6.00 (peptide amide backbone), 5.28–5.14 (PLGA, CH), 4.96–4.84 (PLGA, CH2),
3.30 (en, CH2), and 1.47 (PLGA, CH3).
4.5. Nuclear Magnetic Resonance (NMR) Analysis
All Nuclear Magnetic Resonance (NMR) spectra were recorded at 28 ◦C using an Agilent 600 MHz
(14 T) spectrometer equipped with a DD2 console and a OneNMR HX probe. The samples (1 mg) were
dissolved in 600 µL of 99.9% deuterated solvent (Sigma–Aldrich). 1H 1D spectra were recorded using
256 scans to obtain a good signal-to-noise ratio for peptides, en and rhodamine. A saturation PRESAT
pulse sequence was used to reduce residual peaks of water at 3.33 ppm. Spectra were transformed and
analyzed using VNMRJ 4 software and the chemical shift scale was referenced to the solvent residual
peak signal.
4.6. NP Preparation
Rhodaminated PELGA-Peptide nanoparticles were prepared by using the nanoprecipitation
method [32].
In summary, the proper amounts of co-polymers and conjugates (Table 2) were dissolved in
acetone and mixed. The final volume was adjusted to 1.3 mL. Afterwards, the solution was added
dropwise (6 mL/h) with a syringe pump into 12.5 mL of distilled water under magnetic stirring
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(400 rpm). The solution was kept under magnetic stirring until complete evaporation of the organic
solvent (3–5 h) was obtained. The obtained NP suspension was sterilized with a 0.22 µm membrane
filter. Lastly, the volume of the solution was reduced to 1 mL using Amicon® Ultra-4 centrifugal
filter. The final NP concentration (mg/mL of polymeric species) was estimated by fluorescence
intensity measurements of rhodamine-PLGA using a Victor 2 spectrofluorometer (Perkin Elmer Wallac,
Turku, Finland) that were compared to fluorescence intensity of the initial NP concentration before
filtration. Three different batches of NP formulation were prepared for all the experiments.
4.7. Cell Culture
Immortalized mouse cerebral endothelial bEnd.3 cells (American Type Culture Collection,
Manassas, VA, USA) were grown at 37 ◦C and 5% CO2 in DMEM with 4.5 g/L w/o phenol red
(Gibco Thermo Fisher, USA), supplemented with 10% FBS, 3.7 g/L sodium bicarbonate and 4 mM
glutamine, 100 U/mL penicillin and 0.1 mg/mL streptomycin, and 1% non-essential amino acids.
bEnd.3 cells used in all experiments were seeded at a passage of 21–30.
4.8. Cellular Uptake and Co-Localizations
For co-localization experiments, 1× 104 bEnd.3 cells were seeded on round 12 mm-diameter glass
coverslips placed inside the wells of a 24-well plate. Cells were incubated for 24 h with 0.1 mg/mL
NPs at 37 ◦C and 5% CO2. After incubation, samples were washed two times with PBS to remove
non-internalized NPs and were fixed with 4% paraformaldehyde for 20 min. For lysosome staining, the
fixed cells were permeabilized with 0.05% saponin-PBS for 10 min and blocked with FBS-PBS 10% for
20 min at room temperature. Lysosomes were localized with rabbit Abcam®anti-LAMP-2 polyclonal
primary antibody (Abcam, Cambridge, UK, 1 mg/mL) diluted 1:150 in FBS-PBS 10% after 1 h at room
temperature in a humidified chamber. This was completed with Alexa Fluor®488 anti-rabbit secondary
antibody (Abcam, 1 mg/mL) diluted 1:200 in FBS-PBS 10% and incubated for 30 min. The cell nuclei
were stained with DAPI (Sigma-Aldrich S.r.l.). Lastly, coverslips were mounted on glass slides with
PBS/glycerol (1:1) solution and immunofluorescence analyses were performed by using a confocal
laser scanning microscope (Leica TCS SP5 MP, Weitzlar, Germany).
4.9. Permeability
bEnd.3 cells were seeded at a density of 3 × 104 cells/cm2 on Transwell permeable inserts
(6.5 mm diameter, 3 µm pore size, Corning Incorporated, Corning, NY, USA), n = 3 inserts were
seeded for each sample and the experiments were performed in triplicate. Trans Endothelial Electrical
Resistance (TEER) was measured by using Millicell1-ERS voltohmmeter (Millipore, Billerica, MA, USA).
Permeability experiments were performed 7 days from the seeding, which allowed sufficient time
for the cells to form the tight junctions. On the day of the experiment, the Transwell insert filter
was washed with PBS and then the media of the donor chamber was filled with 150 µL cell culture
medium without phenol red containing 0.1 mg/mL of NPs while the acceptor chamber is filled with
400 µL of cell culture medium. The samples of 400 µL were drawn every 30 min for 2 h from the
acceptor chamber and were then replaced with the same amount of fresh medium. The experiments
were performed in triplicate. The fluorescence tracer concentration in the samples was determined
by a Victor 2 spectrofluorometer and the excitation and emission wavelengths are set to 557 nm and
578 nm, respectively, for NPs. The permeability P of the monolayer was calculated according to the
following equation.
P =
∆CA
∆t ×VA
CD × S , (4)
where ∆CA∆t was the increase in the fluorescence concentration in the acceptor chamber during the time
interval, CD was the fluorescence concentration in the donor chamber (assumed to be constant during
the experiment), VA was the volume of the acceptor chamber, and S was the surface area of the filter.
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4.10. Glycotech
To investigate the ability of NPs to recognize the in vitro BBB under dynamic condition, 4 × 105
bEnd.3 cells were seeded on round glasses (60 mm diameter) placed in Petri dishes (100 mm diameter).
Exactly 3 days from the seeding, the adhesion assays were run by using the Glycotech system.
The system consisted of a poly(methyl methacrylate (PMMA) flow deck with inlet and outlet bores,
a silicon gasket, and a glass coverslip in Figure 5).
Figure 5. Schematic representation of the Glycotech flow chamber for studying NP interaction with the
BBB endothelium.
The silicon gasket separated the acrylic flow deck and the glass and defined the flow area.
The gasket used in the present experiments had a thickness h of 0.01 in and a width w of 1 cm. The inlet
bore was connected to a syringe-pump through a silastic tube and the outlet bore to a reservoir.
The volumetric flow rate Q (10 µL/min) was equal for all the experiments. Based on these data, the
mean velocity was calculated using Equation (1) within the chamber, the shear rate in Equation (2),
and the shear stress at the wall in Equation (3), which had a medium viscosity of 1.2 × 10−2 dyn s/cm2.
The Reynolds number was given by the equation below:
2whρUmean/[(w + h)µ], (5)
and calculated considering the hydraulic diameter of the chamber 2wh/[(w + h)] ∼= 500 µm.
NP suspensions at the final concentration of 0.2 mg/mL in the cell culture medium supplemented
with 40 mM HEPES buffer was flushed by using a 5 mL syringe allocated on a syringe pump. The flow
was driven through the parallel plate flow chamber for 1 h at 37 ◦C in a plexiglass incubator. After the
experiment, cells were fixed after two washes with PBS to remove non-adherent NPs. The percentage
of the mean gray value was analyzed by using the imageJ 1.44 p software package (Nihuo Software,
www.nihuo.com). Data were reported as the percentage of the mean gray value normalized for the
mean gray value of 100% fluorescence intensity of NPs.
5. Conclusions
In this work, biocompatible nanoparticles functionalized with gH and CRT peptides for targeted
drug delivery across the BBB were successfully synthesized. The results clearly indicated that the
percentage of functionalization gH/CRT_33/66 was able to target and cross the in vitro cerebral
endothelium, significantly. The new nanocarrier gH/CRT_33/66, which is made up of FDA-approved
materials, could be considered as a promising strategy for selective and effective administration of
therapeutic compounds to the brain. Further work with drug-loaded NPs is underway.
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